Orexigen Therapeutics — Investor Presentation (April 2010)
66 slides from Orexigen Therapeutics's investor presentation, Apr 13, 2010
Slide 1: Investor Presentation April 2010
EXHIBIT 99.1 Investor Presentation April 2010 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Orexigen cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assumin
Slide 3: Overview
Overview Strong Fundamentals Seasoned team in place to build for regulatory, commercial and partnership success Contrave® + Empatic™ = Obesity franchise Contrave NDA Submitted in March 2010; Empatic Phase II complete Compelling commercial plans to reach target-rich segments, partner for broader mark
Slide 4: Company Background
Company Background Founded 2002 by Michael Cowley (OHSU), Eckard Weber (Domain VC) Model utilizing rational combinations of existing molecules based on understanding of neural circuits that govern weight management Designed to circumvent the body’s natural compensatory mechanisms Synergy in preclini
Slide 5: The Obesity Epidemic is Increasing Healthcare Costs to Alarming Levels
The Obesity Epidemic is Increasing Healthcare Costs to Alarming Levels U.S. obesity rates are projected to . . . Placing increasing cost burden continue growing . . . on the healthcare system Projected US healthcare US obesity rates spend due to obesity 103M $344B 75M 43% 21% 33% $147B 16% 9% The av
Slide 6: The Market Needs Safe and Effective Pharmacotherapy Treatments
The Market Needs Safe and Effective Pharmacotherapy Treatments Diet and lifestyle modifications alone seldom achieve sustainable goals Substantial safety and tolerability concerns and modest weight loss that plateaus have impacted broad use of anti-obesity medications¹ Optimal treatment provides a b
Slide 7: There is Clear Demand for an Rx Solution and Consumers Display a Willingness to Pay
There is Clear Demand for an Rx Solution and Consumers Display a Willingness to Pay Fen-phen Fen-phen experience experience Americans Americans spend spend nearly nearly $60B/yr $60B/yr out- out- demonstrated demonstrated pent-up pent-up demand demand of-pocket of-pocket on on weight weight loss los
Slide 8: Contrave Poised for Regulatory and Commercial Success
Contrave Poised for Regulatory and Commercial Success 8
Slide 9: Scientific Focus: Harness Novel Mechanistic Insights to Treat Obesity
Scientific Focus: Harness Novel Mechanistic Insights Using Well-Known & Safe Therapeutics to Treat Obesity Weight loss is difficult – Diet and exercise often fail – Compensatory biologic mechanisms exist to conserve energy & body weight Hypothalamus is at the center of energy homeostasis and weight
Slide 10: Novel Scientific Rationale for Contrave Addresses Biology and Behavioral Drivers
Novel Scientific Rationale for Contrave Addresses Biology and Behavioral Drivers of Consumption Bupropion Stimulates Impact Biology: POMC (proopio- MC-4 Increase firing of melanocortin) neuron POMC neuron to -MSH to initiate weight loss reduce hunger and Naltrexone Prevents ß-Endorphin raise metabol
Slide 11: Proving the Hypothesis: Demonstrating Synergy in MOA
Proving the Hypothesis: Demonstrating Synergy in MOA Sample recordings from hypothalamic POMC cells 10 M BUP 12 10 8 10 M BUP + 1 M NAL 6 12 4 10 2 0 8 -500 0 500 1000 1500 2000 Time (sec) 6 4 1 M NAL 12 2 10 8 0 6 -500 0 500 1000 1500 4 Time (sec) 2 0 -500 0 500 1000 1500 2000 2500 Time (sec) Recor
Slide 12: Results from Phase 2b Demonstrated Superiority of the Combination
Results from Phase 2b Demonstrated Superiority of the Combination Against Individual Components Placebo Nal Bup Contrave16 Contrave32 Contrave48 (Completer N=60) (Completer N=33) (Completer N=36) (Completer N=32) (Completer N=38) (Completer N=18) *Weight loss at 24 weeks (for comparison only) COMPLE
Slide 13: Contrave Addresses All Elements of FDA Guidance, NDA Submitted March 2010
Contrave Addresses All Elements of FDA Guidance, NDA Submitted March 2010 Contrave Key elements of FDA guidance Program (n=4,536) Statistical Significance on Co-Primary Weight Loss Endpoints Efficacy Benchmark (5% Categorical Response OR 5% Placebo Subtracted AND p<0.05) Additional Endpoints Efficac
Slide 14: Phase III Program Designed for Regulatory and Commercial Success
Phase III Program Designed for Regulatory and Commercial Success Contrave Obesity Patients Research Enrolled Key Features COR – I 1,742 Two doses (Contrave16 and Contrave32) Contrave32 with re-randomization (Contrave32 or 48) for COR – II 1,496 non-responders after Week 28 COR-Diabetes 505 Contrave3
Slide 15: COR-I, COR-II and COR-Diabetes: Baseline Characteristics and Disposition
COR-I, COR-II and COR-Diabetes: Baseline Characteristics and Disposition NB-301 NB-303 NB-304 Average Age 44 44 54 Sex, Female 85% 85% 56% Race, White 75% 84% 79% Tobacco Use 34% 37% 46% Weight (kg) 100 100 106 BMI 36 36 37 Waist Circumference (cm) 109 109 115 Systolic BP (mm Hg) 119 118 125 Diastol
Slide 16: COR-I and COR-II: Categorical Weight Loss at Week 56 for ITT
COR-I and COR-II: Categorical Weight Loss at Week 56 for ITT Placebo (N=511) Contrave32 (N=471) Placebo (N=456) Contrave32 (N=702) COR-I COR-II 80 80 60 60 * * 50.5% 48.0% 40 40 * 28.3% * 24.6% 20 20 17.1% 16.4% * * 13.5% 11.9% 7.4% 5.7% 2.0% 2.4% 0 0 5% 10% 15% 5% 10% 15% Data are for the ITT-LOCFp
Slide 17: COR-I and COR-II: Categorical Weight Loss at Week 56 for ITT & Completers
COR-I and COR-II: Categorical Weight Loss at Week 56 for ITT & Completers Placebo (N=290) Contrave32 (N=296) Placebo (N=267) Contrave32 (N=434) COR-I COR-II 80 80 * * 64.9% 61.8% 60 60 * 39.4% 40 * 40 34.5% 23.1% 21.7% * * 20 17.2% 20 18.9% 10.7% 7.9% 3.1% 3.4% 0 0 5% 10% 15% 5% 10% 15% Data are for
Slide 18: Contrave Exceeded FDA Efficacy Benchmark across the Phase III Program
Contrave Exceeded FDA Efficacy Benchmark across the Phase III Program % Placebo-ITT Contrave32 -ITT % of Patients Losing >5% of Body Weight Efficacy benchmark COR-I COR-II COR-Diabetes COR-BMOD Key Conclusions In all of our PhaseIII trials, Contrave crossedthe categorical efficacy benchmark In COR I
Slide 19: Across the Phase 3 Program, Contrave Delivered Significant Sustained Weight Loss
Across the Phase 3 Program, ContraveDelivered Significant Sustained Weight Loss Placebo Contrave16 Contrave32 Observed ITT-LOCF Observed ITT-LOCF 0 0 -2 -1.3% -2 -1.4% -1.2% -1.9% -4 -4 -5.0%* COR-I COR-II -6 -6.8%* -6 -6.1%* -6.4%* -8 -8 -8.2%* -8.1%* -10 -10 -12 -12 0 8 16 24 32 40 48 56 56 0 8 16
Slide 20: COR Program: Excess Weight Loss
COR Program: Excess Weight Loss COR-I COR-II COR-BMOD COR-Diabetes Placebo NB32 Placebo NB32 Placebo+BMODNB32+BMOD Placebo NB32 N=290 N=296 N=267 N=434 N=106 N=301 N=100 N=175 0 0 0 0 -4.7% -10 -6.7% -10 -10 -10 -6.7% -20 -20 -20 -20 -21.5% * -30 -30 -30 -25.1% -30 -30.0% * -31.7% * -40 -40 -40 -40
Slide 21: Treatment with Contrave Delivered Expected Improvements in Cardiometabolic Risk Markers
Treatment with Contrave Delivered Expected Improvements in Markers of Cardiometabolic Risk COR-I COR-II Placebo Contrave32 Placebo Contrave32 N= 290 N=296 N=267 N=434 Waist circumference (cm), Baseline 109-110 cm -2.7 ± 0.5 -6.9 ± 0.5* -2.1 ± 0.5 -7.1 ± 0.4* Fasting triglycerides (mg/dL) Baseline 12
Slide 22: More Significant Improvements Were Observed in High-risk Subgroups
More Significant Improvements Were Observed in High-risk Subgroups COR-I COR-II Placebo NB32 Placebo NB32 Waist circumference, males >102, females >88 cm -2.8 ± 0.5 -7.1 ± 0.5* -2.2 ± 0.5 -7.3 ± 0.4* Baseline 110-111 cm (n=282) (n=279) (n=254) (n=410) Fasting triglycerides, 150 mg/dL -32.0 ± 10.4 -6
Slide 23: Contrave Demonstrated Statistically Significant Benefits in Quality of Life
Contrave Demonstrated Statistically Significant Benefits in Quality of Life Placebo Contrave16 Contrave32 COR-I 25 20 * * * 15 * * * * * 10 * * * 5 0 b Physical Self- Sexual Public TOTAL Work a c a Function esteem c Life b Distress 20 Placebo Contrave32 COR-II 15 * * * * 10 * 5 0 TOTALb Physical Sel
Slide 24: Most Common Treatment-Emergent Adverse Events across COR-I, COR-II and COR-Diabetes
Most Common Treatment-Emergent Adverse Events across COR-I, COR-II and COR-Diabetes NB-304 NB-301 & NB-303 (Diabetes) Placebo Contrave 16 Contrave32 Contrave32 Overall Treatment-Emergent 68-85% 80% 83-86% 90% Adverse Events ‡ Nausea 5% – 7% 27% 29% – 30% 42% Constipation 6% – 7% 16% 16% – 19% 18% He
Slide 25: Treatment Discontinuations due to Adverse Events
Treatment Discontinuations due to Adverse Events NB-304 NB-301 & NB-303 (Diabetes) Placebo Contrave16 Contrave32 Contrave32 Overall Discontinuation Rate 41% - 50% 51% 46 – 49% 48% Discontinuation Rate Due to AEs 10% – 15% 22% 20% – 24% 29% Nausea + 5% 6% 10% Headache + 2% 1% – 3% 2% Dizziness + 2% +
Slide 26: Incidence of Nausea is Mostly Mild to Moderate, Transient
Incidence of Nausea is Mostly Mild to Moderate, Transient and Occurs Largely in the First Month Placebo Contrave N=1061 N=2134 100 100 Escalation Escalation period period 15 15 10 Mild 10 Mild Moderate Moderate Severe Severe 5 5 0 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 4 8 12 16 20 24 28 32 36 40
Slide 27: After Completing Dose Escalation Patients Tended to Remain in Treatment
After Completing Dose Escalation Patients Tended to Remain in Treatment All Phase III Contrave Treatment All Phase III Placebo Treatment Groups Groups Weekly D/C Cause of discontinuation Weekly D/C Rate (%) Rate (%) Other Reason Contrave Lost to Follow-Up Placebo N=1,594 completed (52%) N= 763 compl
Slide 28: Safety Experience in COR Program
Safety Experience in COR Program Category Phase III Program Summary Serious Adverse Events Attributed to Seven events : Cholecystitis (2), seizure (2), palpitations (1), paresthesia (1) and Contrave vertigo (1) Cardiovascular SAEs Similar rates between Contrave and placebo; one death on Contrave Dep
Slide 29: Fundamental Strengths Make Orexigen an Ideal Partner
Fundamental Strengths Make Orexigen an Ideal Partner 29
Slide 30: If Approved, Contrave and Empatic Enable the Building of a Franchise
If Approved, Contrave and Empatic Enable the Building of a Franchise Contrave, if approved, positioned as first line obesity therapy for broad segments of the market Weight management is an important element of managing existing cardio-metabolic disease Multiple potential new indications and importa
Slide 31: Patients On Contrave Lost Meaningful Weight – And Kept It Off
Patients On Contrave Lost Meaningful Weight – And Kept It Off COR Program: Observed Case % COR Program: Categorical Weight Loss Weight Loss Week 0 Week 14 Week 28 Week 42 Week 56 Avg COR-I loss: % of 39 lbs COR-II Patients COR-BMOD Losing Avg Avg loss: >10% loss: 34 lbs of 35lbs 8.2% Body Weight 11.
Slide 32: Contrave is Uniquely Positioned for Significant Segments of the Obese Population
Contrave is Uniquely Positioned for Significant Segments of the Obese Population A Typical Has diabetes and/or Obese Patient: dyslipidemia 62% Has difficulty controlling eating in 50% response to food cravings Is depressed or has 63% depressive symptoms Is female treatment 73% seeker, often of child
Slide 33: Diabetes and other Metabolic Risk Factors Improve with Contrave
Diabetes and other Metabolic Risk Factors Improve with Contrave A Typical Obese Patient: Has diabetes and/or 62% dyslipidemia Has difficulty controlling eating in 50% response to food cravings Is depressed or has 63% depressive symptoms Is female treatment 73% seeker, often of child bearing age Sour
Slide 34: Weight Management Must Become A Cornerstone Of Diabetes Treatment
Weight Management Must Become A Cornerstone Of Diabetes Treatment There is high awareness that weight control is extremely important for people with diabetes Approximately 80% of people Control Weight with diabetes are overweight/obese* Many diabetes meds lead to weight gain Diabetes Currently, phys
Slide 35: Diabetic Patients on Contrave Lost Weight and Improved Glycemic Control
Diabetic Patients on Contrave Lost Weight and Improved Glycemic Control Placebo-subtracted HbA1c Observed Case Analysis (Contrave32) Key Measures (ITT-LOCF) 1 Body Weight Improved Week 0 Week 14 Week 28 Week 42 Week 56 1 HbA1c (%) Improved Placebo- subtracted 1 Change in % of Subjects with HbA1c <7.
Slide 36: Contrave Improved Metabolic Parameters in High Risk Subgroups
Contrave Improved Metabolic Parameters in High Risk Subgroups Waist Circumference HDL Cholesterol P < 0.05 n: 282 279 n: 254 410 P < 0.05 n: 122 121 n: 117 184 P < 0.05 P < 0.05 Placebo Triglycerides Contrave32 HS-CRP n: 82 87 n: 69 135 n: 163 177 n: 144 261 P < 0.05 P < 0.05 P < 0.05 P < 0.05 Data
Slide 37: Contrave is the only Obesity Drug that can Address Control of Eating
Contrave is the only Obesity Drug that can Address Control of Eating in Response to Food Cravings A Typical Obese Patient: Has diabetes and/or 62% dyslipidemia Has difficulty controlling eating in 50% response to food cravings Is depressed or has 63% depressive symptoms Is female treatment 73% seeke
Slide 38: Both Physicians and Patients Blame Behavior for Obesity
Both Physicians and Patients Blame Behavior for Obesity Patients place much of the blame for Half of obese patients self- their weight on poor eating habits identify as having eating Perceived causes of obesity control issues 100 Half of obese patients 80 acknowledge they Individual choices, consume
Slide 39: Contrave Patients Experienced Statistically Significant Improvements in Eating Control
Contrave Patients Experienced Statistically Significant Improvements in Eating Control Question: How difficult has it been to control your eating? Question: How difficult has it been to resist any food cravings? Contrave32 Less More Placebo *P<0.05 vs. Placebo; ITT-LOCF (all randomized patients with
Slide 40: Obese With Depressive Symptoms Is An Attractive Future Opportunity For Contrave
Obese With Depressive Symptoms Is An Attractive Future Opportunity For Contrave A Typical Obese Patient: Has diabetes and/or 62% dyslipidemia Has difficulty controlling eating in 50% response to food cravings Is depressed or has 63% depressive symptoms Is female treatment 73% seeker, often of child
Slide 41: Obesity is Associated with an Increased Risk of Depression
Obesity is Associated with an Increased Risk of Depression Physicians report that approximately 1/3 of obese patients are taking pharmacologic therapy for depression Another 1/3 of obese patients display signs and symptoms of untreated depression Antidepressants in Obese Population Bupropion is alre
Slide 42: Bupropion Study in the Obese Depressed
Bupropion Study in the Obese Depressed Mean change from baseline body • A 26-week randomized, DBPC study weight (ITT) examining bupropion SR in 422 obese adults with depressive symptoms • Randomized 1:1 to 300mg Bupropion SR or placebo • Baseline BDI-II score of 10-30 • Study demonstrated weight los
Slide 43: Open Label Study: Contrave Reduced Weight and Depressive Symptoms
Open Label Study: ContraveReduced Weight and Depressive Symptoms in Obese Depressed Patients Inventory of Depressive Symptoms (Observed Case) In a 24-week trial of obese Week 0 Week 12 Week 24 depressed patients, Contrave Severely depressed significantly improved measures of depression Moderately de
Slide 44: Approximately 5 Million Patients (>50% of Bupropion Users) Had a BMI of 27 or Greater
Approximately 5 Million Patients (>50% of Bupropion Users ) Had a BMI of 27 or Greater 2009 Bupropion Use by BMI 19.9, 3.9% 100% = 23.6m TRx Source: IMS NPA Jan – Dec 2009; SDI/Verispan occurrences of bupropion by BMI, Jan – Dec 2009; bupropion defined as any branded or generic form; 2.6x refill rat
Slide 45: Contrave's Profile Is Ideally Suited For Obese Women Of Child-Bearing Age
Contrave’s Profile Is Ideally Suited For Obese Women Of Child-Bearing Age A Typical Obese Patient: Has diabetes and/or 62% dyslipidemia Has difficulty controlling eating in 50% response to food cravings Is depressed or has 63% depressive symptoms Is female treatment 73% seeker, often of child bearin
Slide 46: Contrave may Become the Logical Therapeutic Choice in Women of Child-bearing Age
Contrave may Become the Logical Therapeutic Choice in Women of Child-bearing Age Women are more proactive in Majority of the obesity RXs today go addressing weight to women of child-bearing age 63% of women vs. 40% of men initiated a conversation with physician about weight Women are 2.5x more likel
Slide 47: Multiple Potential New Indications and Important Sub-populations for Further Study
Multiple Potential New Indications and Important Sub-populations for Further Study Available obese population Obese with diabetes and/or dyslipidemia 62% Obese who report uncontrollable food 50% cravings Depressed or has 63% depressive symptoms Treatment seeking obese who are female, often of 73% ch
Slide 48: Smoking Cessation while Reducing Weight Gain Represents an Attractive Follow-on Indication
Smoking Cessation while Reducing Weight Gain Represents an Attractive Follow-on Indication for Contrave Numerous studies reveal that post-cessation weight gain is a major barrier for smokers to try quitting and a driver of relapse Payors and employers are encouraging people to quit and paying for sm
Slide 49: Contrave POC Study in Obese Smokers: Compelling Quit Rates without Typical Weight Gain
Contrave POC Study in Obese Smokers: Compelling Quit Rates without Typical Weight Gain In a 24-week open label trial, Sustained Smoking Cessation Contrave significantly reduced Rates cigarette use among obese patients trying to quit smoking In contrast to available therapies for smoking cessation, C
Slide 50: Fundamental Strengths Make Orexigen an Ideal Partner
Fundamental Strengths Make Orexigen an Ideal Partner 50
Slide 51: Empatic is More Effective than its Individual Components
Empatic is More Effective than its Individual Components Empatic120 Empatic360 Mean % Weight Loss (ITT-LOCF) Mean % Weight Loss (ITT-LOCF) n=75 n=81 n=77 n=81 n=75 n=81 n=158 n=164 P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 51
Slide 52: Empatic Demonstrates Early and Progressive Weight Loss
Empatic Demonstrates Early and Progressive Weight Loss Observed Case Analysis At 24 weeks, Empatic demonstrates: Clinically meaningful weight loss No evidence of plateau Both Empatic doses appear efficacious and could provide dosing flexibility Note : All differences between Empatic and placebo high
Slide 53: Most Common Treatment-Emergent Adverse Events and Reasons for Discontinuation
Most Common Treatment-Emergent Adverse Events and Reasons for Discontinuation Placebo Empatic120 Empatic360 (N=89) (N=93) (N=182) Subjects with 1 Treatment-Emergent AE 62.9% 78.5% 83.5% Headache 3.4% 12.9% 14.8% Insomnia 4.5% 15.1% 12.1% Nausea 5.6% 7.5% 12.1% Constipation 0% 6.5% 12.1% Overall Disc
Slide 54: Safety Experience with Empatic
Safety Experience with Empatic Adverse events and laboratory findings appeared to be consistent with the individual components of Empatic – There were no serious adverse events attributed by investigators to study drug There were no statistically or clinically meaningful differences between Empatic
Slide 55: Empatic Next Steps
Empatic Next Steps Phase III planning underway to be ready for EOP2 – Benefit of combination therapy proven in Phase 2b – Comfortable with dose range – Fast-follower approach ideas to be incorporated into Phase 3 design – Positioning as complementary program will make Orexigen franchise more competi
Slide 56: Fundamental Strengths Make Orexigen an Ideal Partner
Fundamental Strengths Make Orexigen an Ideal Partner 56
Slide 57: Orexigen Has Assembled a Proven Team for Regulatory and Commercial Success
Orexigen Has Assembled a Proven Team for Regulatory and Commercial Success Team has been successful delivering: 23 NDAs 15 FDA advisory panels 25 product launches 20 co-promotions and marketing collaborations Significant experience with metabolic and cardiovascular therapeutics 57
Slide 58: Proven Team for Commercialization
Proven Team for Commercialization 20-Year Veteran of Amgen – Including: Michael Narachi GM of Anemia Business Unit President and CEO Global Team Leader, Neupogen Head of Licensing and Business Development Mark Booth President, Takeda Pharmaceuticals North America Chief Commercialization Officer Seni
Slide 59: Script Volume Poised to Expand 3-4x Over the Next Five Years
Script Volume Poised to Expand 3-4x Over the Next Five Years – Price Shift Provides Additional Upside Within 1 year of the Redux launch, market TRx volume increased ~3x (‘96 vs. ‘95) 7M ~3x 21M Physicians state they are only Physicians state they would treat treating a quarter of obese patients who
Slide 60: Summary of Orexigen Conjoint Market Research
Summary of Orexigen Conjoint Market Research The obesity market is poised to expand ~3-4-fold within a few years post-launch of new agents Market will shift from a largely generic one to a mix of both branded and generic products, thereby dramatically increasing the dollar market size New agents are
Slide 61: With Little Current Promotion, a Focused Primary Care Sales Force is Highly Leverageable
With Little Current Promotion, a Focused Primary Care Sales Force is Highly Leveragablein this Space Diabetes: Top 8 Hypertension: Top deciles ~57,000 8 deciles ~51,000 physicians physicians 150 reps can 500 reps can cover target the ~15K the ~40-60K high obesity prescribers of drugs prescribing for
Slide 62: Commercial Strategy: Leverage Small Number of Motivated Obesity Treating Physicians
Commercial Strategy: Leverage Small Number of Motivated Obesity Treating Physicians, and Go Broader with a Partner Orexigen obesity specialty sales force: Rapidly grab the low hanging fruit 150 rep sales force can reach the 500 rep sales force can top 7 deciles of current obesity cover top 5 deciles
Slide 63: Fundamental Strengths Make Orexigen an Ideal Partner
Fundamental Strengths Make Orexigen an Ideal Partner 63
Slide 64: Our Deal Process is on Track
Our Deal Process is on Track Broad outreach to suitable pharma companies – Focus on dialog with commercial decision makers – Structured, competitive process with deliberate timetable to enable partner to accomplish critical launch prep well in advance of approval Orexigen market research, positionin
Slide 65: Orexigen: An Attractive Partner for Three Key Reasons
Orexigen: An Attractive Partner for Three Key Reasons 65
Slide 66: The Orexigen Opportunity
The Orexigen Opportunity Obesity: The next big therapeutic opportunity Orexigen - Only company with two late stage obesity programs Contrave profile for first-line therapy: Uniquely positioned to meet the needs of the obese patient Empatic - Complementary to Contrave Pipeline – A range of differenti
Orexigen Therapeutics — Investor Presentation (April 2010) on 6ix